pipette
ESEspañol

Neuroprotective Effects of the Purine-Derived Compound ITH15004 Against Nigericin- and Mitochondria-Induced Toxicity in NSC-34 Motor Neuron-like Cells

M. Olazabal, R. De Pascual, P. K. de Moraes Berenguel Lossavaro, S. Ciach, M. F. Cano-Abad

Preprint

In the authors' words

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by the progressive degeneration of motor neurons. Most patients die within 3 to 5 years of diagnosis, primarily due to respiratory failure, and effective therapeutic options remain limited. Mitochondrial dysfunction, oxidative stress, calcium dysregulation, and neuroinflammation are key contributors to ALS pathogenesis. In this study, we evaluated the potential neuroprotective effects of ITH15004, a novel compound with modulatory effects on P2X7 purinergic receptors, in an in vitro model using NSC-34 motor neuron-like cells. Cellular stress was induced using oligomycin (10 uM) and rotenone (30 uM), inhibitors of mitochondrial oxidative phosphorylation; nigericin (5 uM), a K+/H+ ionophore that disrupts ionic homeostasis; and extracellular ATP (1 mM), a purinergic receptor agonist. MTT-reducing activity was assessed as an indicator of cellular metabolic activity, while caspase-3/7 activity was measured to evaluate apoptotic responses. Intracellular ATP levels, cytosolic calcium responses, and cytochrome c and VDAC1 protein abundance were also analysed. ITH15004 significantly improved MTT-reducing activity following exposure to ATP, oligomycin/rotenone, and nigericin. In addition, ITH15004 partially restored intracellular ATP levels following nigericin treatment and significantly reduced nigericin-induced caspase-3/7 activation. Western blot analysis further revealed significant changes in cytochrome c and VDAC1 protein levels in response to ITH15004 treatment. These findings indicate that ITH15004 attenuates cellular damage induced by different stressors in NSC-34 cells and modulates several parameters associated with cellular energy status and apoptotic signalling. Further studies are needed to establish its mechanisms of action and assess its therapeutic potential in ALS.

Main resultLimitation the authors admit

Appeared: Tuesday, November 17. bioRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.11.13.766254